Serious renal impairment occurs rarely with use of tenofovir DF

HIV Clinical Trials

Volumn 7, Issue 2, 2006, Pages 55-58

  Scott, James D ^a,b,c   Wolfe, Peter R ^b   Bolan, Robert K ^c   Guyer, Bill ^d  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Pacific Oaks Medical Group   (United States)

^c LOS ANGELES LGBT CENTER   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

Pharmacology; Renal; Tenofovir

Indexed keywords

CREATININE; DIDANOSINE; INDINAVIR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; CREATININE; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHONIC ACIDS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 33746179090     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/2TAJ-QPD1-TYAE-QAK5     Document Type: Article

References (24)

1. Staszewski S, Gallant JE, Pozniak AL, et al. Three-year analysis of the renal safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavrienz (EFV) and anti-retroviral naive patients. Presented at the XV International AIDS Conference; 2004; Bangkok, Thailand.
2. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292(2):191-201.
3. Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS. 2003;17:2543-2544.
4. Peyriere H, Reyenes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-273.
5. Schaaf B, Aries P, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:e41-43.
6. Zimmerman AE, Pizzoferrato T, Bedford J, Morris AB, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283-290.
7. DuPont C, Meier F, Loupy A, Page B, Rouvieix E. Acute renal failure and tenofovir: 2 new cases. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 694.
8. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003;17(6):935-937.
9. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324(6):342-344.
10. Gaspar G, Monereo A, Garcia-Reyne A, Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18(3):351-352.
11. Rollot F, Nazal E, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-176.
12. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070-1073.
13. Verhelst D, Monge M, Meynard J, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40(6):1331-1333.
14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. Scott JD, Wolfe RR, Quiros J, Behrooznia E, Guyer B, Bolan RK. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices. In: Program and abstracts of the International AIDS Conference; 2004; Bangkok, Thailand. Abstract TuPeB4632.
16. Scott JD, Wolfe RR, Chow J, Guyer B, Bolan RK. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices. Presented at: ASHP-Midyear Clinical Meeting; 2003; New Orleans. P448E.
17. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
18. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61(1):1-6.
19. Cihlar T, Ho ES, Lin DC, Mulato AS. Human Renal Organic Anion Transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20(4-7):641-648.
20. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489-1495.
21. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function in patients treated with tenofovir DF compared to nucleoside reverse transcriptase inhibitors. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA.
22. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared to nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1198.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
24. Scott JD, Shibuyama S, Anderson D, Bolan RK. Rare occurence of renal impairment when retrospectively evaluating the use of tenofovir DF when used >12 months. In: Program and abstracts of the 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland. Abstract 9.1/2.